Securities code: 603716 securities abbreviation: Thalys Medical Technology Group Corporation(603716) Announcement No.: 2022-004
Bond Code: 113601 bond abbreviation: celi convertible bond
Thalys Medical Technology Group Corporation(603716)
Stock trading abnormal fluctuation announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
The shares of Thalys Medical Technology Group Corporation(603716) (hereinafter referred to as “the company”) have been traded for 3 consecutive years
The cumulative deviation of closing price increase in the last trading days (January 14, January 17 and January 18, 2022) exceeded
20%, according to the relevant provisions of the trading rules of Shanghai Stock Exchange, it belongs to abnormal fluctuation of stock trading
Shape.
After self inspection by the company, the company reported to the controlling shareholder saihai (Shanghai) Health Technology Co., Ltd. (hereinafter referred to as
“Saihai technology”) and Mr. Wen Wei, the actual controller, sent a letter to verify that saihai technology was motivated by the introduction of strategic investors
Considering the improvement of corporate governance structure, preparations are being made for the reduction of shares of the company through agreement transfer
It is still in the negotiation stage, and there is still great uncertainty about relevant matters. In addition, controlling shareholders and actual controlling shareholders
The maker has no material information that should be disclosed but not disclosed.
At present, the company’s production and operation activities are normal, and there is no major adjustment to the market environment and industrial policies
All subordinate businesses of the company are carried out normally, and the internal production and operation order is normal.
The New Coronavirus antigen detection kit developed by the company has been approved by the European Union CE.
It is sold in the EU market, but the above product certification is not exclusive to the company, and there are many similar products or their products in the market
He said that the company’s related products have not yet been sold in the EU, which is not important to the company’s performance
Big impact. Investors should pay attention to investment risks, make rational decisions and invest prudently.
1、 Details of stock trading (abnormal) fluctuations
The company’s shares were continuously on January 14, 2022, January 17, 2022 and January 18, 2022
Within 3 trading days, the deviation of daily closing price increase exceeds 20% in total, according to the trading rules of Shanghai Stock Exchange
The relevant provisions of the rules belong to abnormal fluctuations in stock trading.
2、 Relevant information concerned and verified by the company:
(I) production and operation
According to the company’s self inspection, the company’s production and operation activities are normal, the market environment and industrial policies have not been significantly adjusted, the company’s subordinate businesses are carried out normally, and the internal production and operation order is normal. There are no major issues affecting the abnormal fluctuation of the company’s stock trading price, and there are no major information that should be disclosed but not disclosed. (II) major events
After the company’s self-examination and verification by sending a letter to the controlling shareholder saihai technology and the actual controller of the company, Mr. Wen Wei, as of the date of disclosure of the announcement, saihai technology has considered the normal business needs, the introduction of institutional investors and the improvement of the corporate governance structure, The matter of reducing the company’s shares through agreement transfer is under preparation (relevant tips have been made in the suggestive announcement on the transfer of some shares by agreement and changes in equity by controlling shareholders (Announcement No.: 2021-098) disclosed by the company on November 5, 2021). At present, it is still in the negotiation stage, and there are still great uncertainties in relevant matters. In addition, the company, the controlling shareholder and the actual controller of the company do not have any major information that should be disclosed but not disclosed involving the listed company, including but not limited to major asset restructuring, acquisition, debt restructuring, business restructuring, asset divestiture, asset injection, share repurchase, equity incentive, bankruptcy reorganization Major business cooperation and other major events that have a great impact on the company’s stock trading price.
(III) media reports, market rumors and hot concepts
The New Coronavirus antigen detection kit developed by the company has been approved by the European Union CE, which can be sold in the EU market. However, the above product certification is not exclusive to the company, there are many similar products or other testing products in the market, and the company’s products have not yet been sold in the EU region, which has no significant impact on the company’s performance. Investors should pay attention to investment risks, make rational decisions and invest prudently.
In addition, no major events that have a significant impact on the company’s stock trading price, no media reports or market rumors that need to be clarified or responded to, and no other hot concept matters are involved.
(IV) other stock price sensitive information
According to the company’s self-examination, the company did not find any other major events that may have a great impact on the company’s share price. The controlling shareholders, actual controllers, directors, supervisors and senior managers of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Relevant risk tips
1. On January 14, January 17 and January 18, 2022, the cumulative deviation of the closing price of the company’s shares from the value exceeds 20%. The actual fluctuation range of the stock price excluding the overall factors of the market and the sector is large. The company specially reminds investors to pay attention to stock investment risks, make prudent decisions and invest rationally. 2, the New Coronavirus antigen and antibody detection kit developed by the company has been approved by the European Union CE, and has not yet been launched. Meanwhile, due to the development and control of overseas epidemic situation, the selection of testing methods, the promotion of overseas markets, the degree of customer recognition and so on, the sales situation of the above-mentioned COVID-19 products has great uncertainty.
4、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that as of the date of this announcement, the company has no matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange or the planning, negotiation, intention and agreement related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange Information that may have a great impact on the stock trading price of the company.
5、 Online announcement attachment
Reply to inquiry letter on Thalys Medical Technology Group Corporation(603716) abnormal fluctuation of stock trading
It is hereby announced.
Thalys Medical Technology Group Corporation(603716) board of directors January 19, 2022
